Moraxellaceae

Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Retrieved on:

Wednesday, August 4, 2021

Chemical compounds, Moraxellaceae, Organic compounds, Medical specialties, Bacterial diseases, Antibiotics, Acinetobacter, Multidrug-resistant Gram-negative bacteria, Zoliflodacin, Sulbactam

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Key Points:

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
For more information, visit www.entasistx.com .

Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam

Retrieved on:

Tuesday, July 27, 2021

Health, Articles, Moraxellaceae, Carbapenem, Healthcare-associated infections, Acinetobacter, Antimicrobial resistance, Antibiotic, ESKAPE

WALTHAM, Mass. and SHANGHAI, China and SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is now complete, with top-line data readout anticipated early in the fourth quarter of 2021.

Key Points:

To our knowledge, ATTACK is the largest antibiotic-resistant, pathogen-specific registrational trial to be conducted globally and the first to focus specifically on carbapenem-resistant Acinetobacter infections.
Harald Reinhart, M.D., Chief Medical Officer for Autoimmune and Infectious Diseases at Zai Lab, stated, Infections caused by carbapenem-resistant Acinetobacter spp.
ATTACK is a Phase 3 registrational trial that will evaluate the safety and efficacy of SUL-DUR in patients with confirmed carbapenem-resistant Acinetobacter infections.
ATTACK is a global Phase 3 registration trial that enrolled patients at clinical sites from 17 countries.

Shionogi Announces In Vitro and Real-World Data Presented at ECCMID 2021 Demonstrating Activity of cefiderocol Against Critical Priority Gram-negative Bacterial Pathogens

Retrieved on:

Thursday, July 8, 2021

Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Bacteria, Medical specialties, Moraxellaceae, Gram-negative bacteria, Pathogenic bacteria, Pseudomonadales, Beta-lactam antibiotics, Acinetobacter baumannii, Carbapenem, Acinetobacter, Beta-lactamase, Stenotrophomonas maltophilia

Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations.

Key Points:

Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations.
Carbapenem-resistant A. baumannii (n=96; 40.5%) and carbapenem-resistant P. aeruginosa (n=78; 32.9%) were the most common pathogens.
Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates.
The CARBAR part 1 study: a pooled analysis of the epidemiology data for UK, France and Spain: Bacterial susceptibility & resistance.

Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

Retrieved on:

Thursday, July 1, 2021

Bacteria, Medical specialties, Gram-negative bacteria, Pathogenic bacteria, Moraxellaceae, Infectious diseases, Healthcare-associated infections, Acinetobacter baumannii, Neisseria, Antibiotic, Acinetobacter

ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.

Key Points:

ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.
Similar in vivo efficacy was also demonstrated for the biothreat pathogens Y. pestis and B. pseudomallei.
Entasis demonstrated that ETX0462 was well tolerated in a rat 14-day GLP toxicology study reaching the limit dose of 2,000 mg/kg.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Pseudomonas infections).

Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

Retrieved on:

Friday, June 18, 2021

Moraxellaceae, Bacterial diseases, Medical specialties, Chemical compounds, Bacteriology, Antibiotics, Acinetobacter baumannii, Gram-negative bacteria, Pathogenic bacteria, Acinetobacter, Pseudomonas infection, Zoliflodacin

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.

Key Points:

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.
Entasis will present 11 posters with one oral presentation highlighting ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against Pseudomonas aeruginosa.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
For more information, visit www.entasistx.com.

Medical Students Call for Congressional Action on AMR

Retrieved on:

Tuesday, June 1, 2021

A group of more than 150 medical students from 22 states today called on Congress to make the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act a priority.

Key Points:

A group of more than 150 medical students from 22 states today called on Congress to make the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act a priority.
In a letter to Members of Congress , the students share their firsthand insight into the rising threat of antimicrobial resistance (AMR) among their patients, and the alarming role AMR plays in combatting infectious diseases and preparing for future pandemics.
The students write : In a study of 99 patients infected with COVID-19, bacterial cultures revealed infections of difficult-to-treat superbugs, including A. baumannii, K. pneumoniae, and A. flavus.
AMR is a threat to all of us, and the time to prepare for it is now.

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

Retrieved on:

Monday, May 3, 2021

Bacteria, Medical specialties, Bacteriology, Gram-negative bacteria, Moraxellaceae, Pathogenic bacteria, Gonorrhea, Infectious causes of cancer, Acinetobacter, Carbapenem, Neisseria gonorrhoeae, Neisseria

Entasis\xe2\x80\x99 pipeline includes sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant Acinetobacter baumannii infections, and zoliflodacin for uncomplicated gonorrhea, including infections caused by drug-resistant strains of Neisseria gonorrhoeae.

Key Points:

Entasis\xe2\x80\x99 pipeline includes sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant Acinetobacter baumannii infections, and zoliflodacin for uncomplicated gonorrhea, including infections caused by drug-resistant strains of Neisseria gonorrhoeae.
At the initial closing, which occurred on May 3, 2021, Innoviva purchased approximately 3.7 million shares of common stock and warrants to purchase approximately 3.7 million shares of common stock for an aggregate purchase price of approximately $7.5 million.
For more information, visit www.entasistx.com .\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on Entasis\xe2\x80\x99 expectations and assumptions as of the date of this press release.

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Retrieved on:

Thursday, March 4, 2021

Medical specialties, Moraxellaceae, Clinical medicine, Health care, Healthcare-associated infections, Acinetobacter, Drug resistance, Infection, Multiple drug resistance

Dr. Hassett, who collaborated with both the United States Air Force and Arch, demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumanniiand Acinetobacter spp.

Key Points:

Dr. Hassett, who collaborated with both the United States Air Force and Arch, demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumanniiand Acinetobacter spp.
These pathogens have been shown to infect soldiers who are injured by gun, shrapnel, burn or blast wounds.
For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com .
For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 [email protected]

Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

Retrieved on:

Thursday, January 7, 2021

Moraxellaceae, Chemical compounds, Medical specialties, Organic compounds, Bacterial diseases, Acinetobacter, Multidrug-resistant Gram-negative bacteria, Zoliflodacin, Sulbactam, Antibiotic

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.

Key Points:

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.
The Companys presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).

FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

Retrieved on:

Wednesday, November 18, 2020

General Health, FDA, Infectious diseases, Health, Pharmaceutical, Health sciences, Medical specialties, Health care, Moraxellaceae, Bacteriophages, Phage therapy, Therapy, Multiple drug resistance, Bacteriophage, Acinetobacter, Drug resistance, Antibiotic

Importantly, once sufficient treatment data is available, we plan to request a meeting with the FDA to raise the possibility of an Emergency Use Authorization (EUA) for PhageBank therapy in COVID-19 patients with suspected or confirmed secondary bacterial infections.

Key Points:

Importantly, once sufficient treatment data is available, we plan to request a meeting with the FDA to raise the possibility of an Emergency Use Authorization (EUA) for PhageBank therapy in COVID-19 patients with suspected or confirmed secondary bacterial infections.
The availability of phage therapy allowed us to reduce the burden of multi-drug resistant Acinetobacter baumannii infection in these patients.
APTs PhageBank approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage.
Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank therapy to treat more than 30 critically ill patients in which standard-of-care antibiotics had failed.